三种乳腺癌化疗方案的药物经济学分析  

Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer

作　　者：徐素梅[1] 吕淑河[2] 王雨露[1] 李岱[1] 徐平声[1] XU Sumeia, LYU Shuheb, WANG Yulua, LI Daia, XU Pingshenga(Xiangya Hospital Central South University, a.National Institution of Drug Clinical Trail, b.Department of Pharmacy, Changsha 410008, Chin)

机构地区：[1]中南大学湘雅医院国家药物临床试验机构,长沙410008 [2]中南大学湘雅医院药学部,长沙410008

出　　处：《中国现代应用药学》2018年第2期271-274,共4页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的从药物经济学角度评价乳腺癌术后3种化疗方案的经济学效果,为临床合理用药提供参考。方法 90例乳腺癌术后患者分为3组[TAC组(多西他赛+多柔比星+环磷酰胺)、PEC组(紫杉醇脂质体+表柔比星+环磷酰胺)、AC组(多柔比星+环磷酰胺)],采用药物经济学的成本-效果分析法对3种化疗方案进行临床病例的回顾性分析比较。结果 3组化疗方案的总体有效率分别为71.87%,73.07%,65.62%;治疗成本分别为11 713.49元,18 197.79元和7 795.82元;成本-效果比分别为162.98,249.04,118.80。化疗不良反应方面,PEC组发生率高于TAC组及AC组。结论 TAC为乳腺癌术后化疗较佳的治疗方案,值得推广。OBJECTIVE To evaluate the cost-effectiveness of three chemotherapy schemes in postoperative treatment of mammary cancer,providing a basis for the further drug administration.METHODS Ninety postoperative patients with mammary cancer were divided into three groups [TAC group（docetaxel ＋ doxorubicin ＋ cyclophosphamide）,PEC group（paclitaxel ＋ epirubicin ＋ cyclophosphamide）,and AC group（doxorubicin ＋ cyclophosphamide）],the cost-effectiveness method in pharmacoeconomics was adopted to analyze retrospectively the three different regimens.RESULTS The overall response rate for TAC,PEC and AC were 71.87%,73.07% and 65.62%,respectively; the costs were 11 713.49,18 197.79 and 7 795.82 yuan,respectively,with corresponding cost-effectiveness ratios of 162.98,249.04 and 118.80.For the chemotherapy toxicity,the PEC group was higher than those of the TAC group and AC group.CONCLUSION Scheme TAC is a better approach for postoperative treatment of soaked mammary cancer.

关 键 词：成本-效果 药物经济学 乳腺癌 敏感度分析 

分 类 号：R969.3[医药卫生—药理学]